176 related articles for article (PubMed ID: 36445781)
1. IFN-γR/STAT1 signaling in recipient hematopoietic antigen-presenting cells suppresses graft-versus-host disease.
Lu C; Ma H; Song L; Wang H; Wang L; Li S; Lagana SM; Sepulveda AR; Hoebe K; Pan SS; Yang YG; Lentzsch S; Mapara MY
J Clin Invest; 2023 Feb; 133(3):. PubMed ID: 36445781
[TBL] [Abstract][Full Text] [Related]
2. IFN-γ receptor-deficient donor T cells mediate protection from graft-versus-host disease and preserve graft-versus-tumor responses after allogeneic bone marrow transplantation.
Sun K; Hsiao HH; Li M; Ames E; Bouchlaka M; Welniak LA; Hagino T; Jagdeo J; Pai CC; Chen M; Blazar BR; Abedi M; Murphy WJ
J Immunol; 2012 Aug; 189(4):2033-42. PubMed ID: 22778394
[TBL] [Abstract][Full Text] [Related]
3. Absence of STAT1 in donor-derived plasmacytoid dendritic cells results in increased STAT3 and attenuates murine GVHD.
Capitini CM; Nasholm NM; Chien CD; Larabee SM; Qin H; Song YK; Klover PJ; Hennighausen L; Khan J; Fry TJ
Blood; 2014 Sep; 124(12):1976-86. PubMed ID: 25079358
[TBL] [Abstract][Full Text] [Related]
4. Graft-versus-host disease causes failure of donor hematopoiesis and lymphopoiesis in interferon-gamma receptor-deficient hosts.
Delisle JS; Gaboury L; Bélanger MP; Tassé E; Yagita H; Perreault C
Blood; 2008 Sep; 112(5):2111-9. PubMed ID: 18552211
[TBL] [Abstract][Full Text] [Related]
5. Donor interleukin-22 and host type I interferon signaling pathway participate in intestinal graft-versus-host disease via STAT1 activation and CXCL10.
Lamarthée B; Malard F; Gamonet C; Bossard C; Couturier M; Renauld JC; Mohty M; Saas P; Gaugler B
Mucosal Immunol; 2016 Mar; 9(2):309-21. PubMed ID: 26153763
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of antigen presentation to T cells in murine graft-versus-host disease: cross-presentation and the appearance of cross-presentation.
Wang X; Li H; Matte-Martone C; Cui W; Li N; Tan HS; Roopenian D; Shlomchik WD
Blood; 2011 Dec; 118(24):6426-37. PubMed ID: 21963602
[TBL] [Abstract][Full Text] [Related]
7. IFN-γ receptor and STAT1 signaling in B cells are central to spontaneous germinal center formation and autoimmunity.
Domeier PP; Chodisetti SB; Soni C; Schell SL; Elias MJ; Wong EB; Cooper TK; Kitamura D; Rahman ZS
J Exp Med; 2016 May; 213(5):715-32. PubMed ID: 27069112
[TBL] [Abstract][Full Text] [Related]
8. Recipient nonhematopoietic antigen-presenting cells are sufficient to induce lethal acute graft-versus-host disease.
Koyama M; Kuns RD; Olver SD; Raffelt NC; Wilson YA; Don AL; Lineburg KE; Cheong M; Robb RJ; Markey KA; Varelias A; Malissen B; Hämmerling GJ; Clouston AD; Engwerda CR; Bhat P; MacDonald KP; Hill GR
Nat Med; 2011 Nov; 18(1):135-42. PubMed ID: 22127134
[TBL] [Abstract][Full Text] [Related]
9. STING negatively regulates allogeneic T-cell responses by constraining antigen-presenting cell function.
Wu Y; Tang CA; Mealer C; Bastian D; Hanief Sofi M; Tian L; Schutt S; Choi HJ; Ticer T; Zhang M; Sui X; Huang L; Mellor AL; Hu CA; Yu XZ
Cell Mol Immunol; 2021 Mar; 18(3):632-643. PubMed ID: 33500563
[TBL] [Abstract][Full Text] [Related]
10. Lack of IFN-γ Receptor Signaling Inhibits Graft-versus-Host Disease by Potentiating Regulatory T Cell Expansion and Conversion.
Zhai N; Liu W; Jin CH; Ding Y; Sun L; Zhang D; Wang Z; Tang Y; Zhao W; LeGuern C; Mapara MY; Wang H; Yang YG
J Immunol; 2023 Sep; 211(5):885-894. PubMed ID: 37486211
[TBL] [Abstract][Full Text] [Related]
11. Absence of Stat1 in donor CD4⁺ T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice.
Ma H; Lu C; Ziegler J; Liu A; Sepulveda A; Okada H; Lentzsch S; Mapara MY
J Clin Invest; 2011 Jul; 121(7):2554-69. PubMed ID: 21670504
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow deficient in IFN-{gamma} signaling selectively reverses GVHD-associated immunosuppression and enhances a tumor-specific GVT effect.
Capitini CM; Herby S; Milliron M; Anver MR; Mackall CL; Fry TJ
Blood; 2009 May; 113(20):5002-9. PubMed ID: 19258593
[TBL] [Abstract][Full Text] [Related]
13. STAT1 regulates IFN-alpha beta- and IFN-gamma-dependent control of infection with Chlamydia pneumoniae by nonhemopoietic cells.
Rothfuchs AG; Trumstedt C; Mattei F; Schiavoni G; Hidmark A; Wigzell H; Rottenberg ME
J Immunol; 2006 Jun; 176(11):6982-90. PubMed ID: 16709859
[TBL] [Abstract][Full Text] [Related]
14. Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ.
Anderson BE; McNiff JM; Jain D; Blazar BR; Shlomchik WD; Shlomchik MJ
Blood; 2005 Mar; 105(5):2227-34. PubMed ID: 15522961
[TBL] [Abstract][Full Text] [Related]
15. Induction of acute GVHD by sex-mismatched H-Y antigens in the absence of functional radiosensitive host hematopoietic-derived antigen-presenting cells.
Toubai T; Tawara I; Sun Y; Liu C; Nieves E; Evers R; Friedman T; Korngold R; Reddy P
Blood; 2012 Apr; 119(16):3844-53. PubMed ID: 22101894
[TBL] [Abstract][Full Text] [Related]
16. STAT1 expression in dendritic cells, but not T cells, is required for immunity to Leishmania major.
Johnson LM; Scott P
J Immunol; 2007 Jun; 178(11):7259-66. PubMed ID: 17513775
[TBL] [Abstract][Full Text] [Related]
17. Prevention of graft-versus-host disease and bone marrow rejection: kinetics of induction of tolerance by UVB modulation of accessory cells and T cells in the bone marrow inoculum.
Oluwole SF; Engelstad K; James T
Blood; 1993 Mar; 81(6):1658-65. PubMed ID: 8453111
[TBL] [Abstract][Full Text] [Related]
18. Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R.
Wilhelm K; Ganesan J; Müller T; Dürr C; Grimm M; Beilhack A; Krempl CD; Sorichter S; Gerlach UV; Jüttner E; Zerweck A; Gärtner F; Pellegatti P; Di Virgilio F; Ferrari D; Kambham N; Fisch P; Finke J; Idzko M; Zeiser R
Nat Med; 2010 Dec; 16(12):1434-8. PubMed ID: 21102458
[TBL] [Abstract][Full Text] [Related]
19. Graft-versus-host disease is independent of innate signaling pathways triggered by pathogens in host hematopoietic cells.
Li H; Matte-Martone C; Tan HS; Venkatesan S; McNiff J; Demetris AJ; Jain D; Lakkis F; Rothstein D; Shlomchik WD
J Immunol; 2011 Jan; 186(1):230-41. PubMed ID: 21098219
[TBL] [Abstract][Full Text] [Related]
20. Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1.
Leng C; Gries M; Ziegler J; Lokshin A; Mascagni P; Lentzsch S; Mapara MY
Exp Hematol; 2006 Jun; 34(6):776-87. PubMed ID: 16728283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
